Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
G+FLAS Life Sciences, Inc. logo — CRISPR

G+FLAS Life Sciences, Inc.

CRISPR

Founded 2014 Korea South Korea South 9 employees Series E Total: $37.90B Biopharma, Biotechnology +2

General Information

Company Name G+FLAS Life Sciences, Inc.
Founded Year 2014
Location Korea South Korea South
Employees 9
Industries Biopharma, Biotechnology, Food and Beverage +1
Funding Stage Series E
Social

BounceWatch is an independent company data service, not affiliated with G+FLAS Life Sciences, Inc.. To contact G+FLAS Life Sciences, Inc., visit gflas.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does G+FLAS Life Sciences, Inc. compare?

A PDF of G+FLAS Life Sciences, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting G+FLAS Life Sciences, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About G+FLAS Life Sciences, Inc.

G+FLAS Life Sciences, Inc., founded in 2014, has positioned itself at the forefront of CRISPR technology advancement. With a focus on developing CRISPR/Cas foundational technologies, the company is innovating in areas critical to human health, including gene therapy drugs, biopharmaceuticals, and novel seeds with desired traits. Based in South Korea, G+FLAS Life Sciences operates in multiple high-impact industries such as Biopharma, Biotechnology, and Life Sciences.

The company last garnered attention from the investment community through a significant KRW3.00B Series E round on 01 June 2022, led by Smilegate Investment. This infusion of capital underscores investor confidence in the company's potential to drive substantial advancements across its targeted sectors. As an innovator in CRISPR applications, G+FLAS Life Sciences is poised for impactful contributions to both human health and agricultural productivity.

Business keywords: CRISPR, genetic engineering, gene therapy, biopharmaceuticals, agricultural biotechnology, innovation, genomics, biomedical research, precision medicine

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series E KRW3.00B 1
Smilegate Investment
Smilegate Investment
01 Jun 2022
Series D KRW6.00B 1
FACT
06 May 2021
Series C KRW12.00B 4
Smilegate Investment New Flight
Smilegate Investment, New Flight +2
31 Jul 2019
Series B KRW14.00B 3
DS Asset Management
DS Asset Management, Timepolio Asset Management +1
30 Jun 2018
Series A KRW2.20B 3
The Wells Investment, Inc.
The Wells Investment, Inc., Ost Investment +1
28 Feb 2017
Seed Round KRW700.00M 2
ActnerLab
ActnerLab, TIPS Program
01 Jan 2016

G+FLAS Life Sciences, Inc. Alternatives & Competitors

View All Alternatives
G+FLAS Life Sciences, Inc. vs
Tessera Therapeutics
Tessera Therapeutics

Pioneering the future of genetic medicine with the power to rewrite the genome and cure diseases at...

21 employees
Biopharma, Biotechnology
G+FLAS Life Sciences, Inc. vs
SonoThera
SonoThera United States

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Series A
54 employees
Biopharma, Biotechnology
G+FLAS Life Sciences, Inc. vs
Virostem Biotechnology
Virostem Biotechnology Turkey

Gene Editing Technologies and Applications

2 employees
Biotechnology, Life Sciences
View all alternatives

FAQ About G+FLAS Life Sciences, Inc.

CRISPR
G+FLAS Life Sciences, Inc. was founded in 2014.
G+FLAS Life Sciences, Inc. is headquartered in Korea South.
G+FLAS Life Sciences, Inc. operates in Biopharma, Biotechnology, Food and Beverage and Life Sciences. Its work centres on CRISPR, genetic engineering, gene therapy and biopharmaceuticals.
G+FLAS Life Sciences, Inc. has approximately 9 employees.
G+FLAS Life Sciences, Inc. has completed 6 funding rounds, raising a total of $37.90B. The latest funding stage is Series E.
Top alternatives and competitors to G+FLAS Life Sciences, Inc. include Tessera Therapeutics, SonoThera, Virostem Biotechnology, Synthego, Mammoth Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
G+FLAS Life Sciences, Inc. and Tessera Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for G+FLAS Life Sciences, Inc., https://bouncewatch.com/company/gflas-life-sciences-inc, updated 12 August 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout